PURPOSE: Recent data suggest that the rate of burnout among oncologists has risen over time. In addition to the negative effect of burnout on individuals, widespread burnout may prevent the oncology workforce from meeting patient care needs. METHODS: ASCO surveyed US-based oncologists in patient care roles about their professional well-being and satisfaction and the effect of both on their career plans. Burnout was assessed using measures of emotional exhaustion and depersonalization from the Maslach Burnout Inventory Human Services Survey. Data from the 2023 survey were compared with data from Shanafelt et al (JCO, 2014) collected about oncologist burnout/well-being in 2013. RESULTS: In all, 328 responses to the 2023 survey were analyzed. Burnout was significantly higher compared with 2013, 45% in 2013 versus 59% in 2023 ( P < .01). In 2023, <25% of oncologists reported feeling satisfied with their work-life integration, compared with nearly 35% in 2013 ( P < .01). Burnout was significantly associated with being a caregiver in one’s personal life, being under age 50 years, and working more than 60 hours per week (all P < .05). Over 20% of respondents reported that it was likely or definite that they would reduce their clinical hours in the next 12 months. Additional practice/administrative support and reducing work hours were identified as potential solutions to improve job satisfaction. CONCLUSION: Oncologists in 2023 are experiencing higher rates of burnout compared with a decade ago. System-based interventions to reduce burnout are necessary to maintaining an adequate workforce to provide care for current and future patients with cancer.
Oncologists face ethical challenges when patients use potentially harmful complementary and alternative medicine in addition to or instead of conventional treatments for their cancer. For example, a patient may forego effective cancer treatment in favor of alternative therapies and suffer significant harm as a result. Similarly, false beliefs about the efficacy of complementary therapies may complicate the process of shared decision making about cancer treatment. In this vignette, we discuss clinicians’ obligations and provide recommendations for ethically sound communication practices in this clinical context.
Shortages of injectable drugs affect many cancer patients and providers in the U.S. today. Scholars and policymakers have recently begun to devote increased attention to these issues, but only a few tangible resources exist to guide clinical oncologists in developing strategies for dealing with drug shortages on a recurring basis. This article discusses existing information from the scholarly literature, policy analyses, and other relevant sources and seeks to provide practical ethical guidance to the broad audience of oncology professionals who are increasingly confronted with such cases in their practice. We begin by providing a brief overview of the history, causes, and regulatory context of oncology drug shortages in the U.S., followed by a discussion of ethical frameworks that have been proposed in this setting. We conclude with practical recommendations for ethical professional behavior in these increasingly common and challenging situations.
In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement includes three recommendations directed to academic medical centers to further this goal: (1) establish reasonable clinical workloads for academic medical oncologists, (2) provide resources to enable medical oncologists to participate in and conduct research, and (3) develop and apply their standards for clinical workloads and research support, as well as career advancement and leadership opportunities, fairly and equitably across academic medical oncologists. Overall, improved career satisfaction is likely to result in retention of oncologists in the workforce. This is critical to support high-quality patient care, educate the next generation of cancer-focused professionals, and accelerate research discovering effective strategies for cancer prevention, diagnosis, and treatment.
The decision in Dobbs v Jackson Women's Health Organization overturned federal protections for abortion rights, making way for states to enact abortion bans with or without exceptions for the health or life of the pregnant patient. Patient care across many areas of medicine including oncology continues to be affected. Although the change in the legal landscape is widely felt, the core ethical considerations for physicians do not change because of restrictions on the practice of medicine. ASCO offers this guidance to assist US oncologists and institutions who must balance limitations with established ethical duties. This paper articulates principles for cancer care and pregnancy, offers a framework for ethical reflection and action for oncologists who care for pregnant patients, and makes recommendations for individual and institutional action to support evidence-based, patient-centered care in the United States where abortion is illegal or access is limited.